{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:38:48Z","timestamp":1783417128697,"version":"3.54.6"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rural and smaller urban settings in Canada are disproportionately impacted by the overdose crisis, highlighting the need for novel public health interventions within these jurisdictions. Tablet injectable opioid agonist therapy (TiOAT) programs have been implemented in select rural communities as a means to address drug-related harms. However, little is known about the accessibility of these novel programs. Therefore, we conducted this study to understand the rural context and factors that affected access of TiOAT programs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between October 2021 to April 2022, individual qualitative semi-structured interviews were conducted with 32 individuals enrolled in a TiOAT program at participating rural and smaller urban sites in British Columbia, Canada. Interview transcripts were coded using NVivo 12 and data were analyzed thematically.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TiOAT access varied considerably. TiOAT delivery in rural settings is complicated due to geographic challenges. Participants who were homeless and staying at a nearby shelter or those in centrally-located supportive housing had minimal issues compared to those living in more affordable housing on the outskirts of town with limited transportation options. Dispensing policies that required daily-witnessed ingestion multiple times daily were challenging for most. Only one site provided evening take-home doses whereas participants at the other site could only resort to the illicit opioid supply to address withdrawal outside of program hours. Participants described the clinics as providing a positive and familial social environment compared to experiences of stigma elsewhere. Medication interruptions did occur when participants were in hospital and custodial settings, leading to withdrawal, program discontinuation, and overdose risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study highlights the beneficial ways in which health services tailored for people who use drugs can create a stigma-free environment with an emphasis on social bonds. Other factors such as transportation access, dispensing policies, and access in rural hospitals and custodial settings produced unique challenges for rural people who use drugs. Public health authorities in rural and smaller settings should consider these factors when designing, implementing, and scaling up future substance use services, including TiOAT programs.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-023-00525-2","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T18:02:54Z","timestamp":1677866574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study"],"prefix":"10.1186","volume":"18","author":[{"given":"Geoff","family":"Bardwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette M.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"525_CR1","unstructured":"Government of Canada. Opioid- and Stimulant-related Harms in Canada (September 2022) 2022. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/. Accessed 1 Dec 2022."},{"issue":"4","key":"525_CR2","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/ADM.0000000000000684","volume":"14","author":"UG Khatri","year":"2020","unstructured":"Khatri UG, Perrone J. Opioid Use Disorder and COVID-19: Crashing of the Crises. J Addict Med. 2020;14(4):e6\u20137.","journal-title":"J Addict Med"},{"issue":"1","key":"525_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","volume":"17","author":"A Dunlop","year":"2020","unstructured":"Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26.","journal-title":"Harm Reduct J"},{"key":"525_CR4","unstructured":"BC Coroners Service. Illicit Drug Toxicity Deaths in BC January 1, 2012 - September 30, 2022 2022. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf. Accessed 1 Dec 2022."},{"key":"525_CR5","doi-asserted-by":"crossref","unstructured":"Strike C, Watson TM. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. International Journal of Drug Policy. 2019.","DOI":"10.1016\/j.drugpo.2019.02.005"},{"issue":"49","key":"525_CR6","doi-asserted-by":"publisher","first-page":"E1731","DOI":"10.1503\/cmaj.77303","volume":"192","author":"A Ryan","year":"2020","unstructured":"Ryan A, Sereda A, Fairbairn N. Measures to support a safer drug supply. Can Med Assoc J. 2020;192(49):E1731.","journal-title":"Can Med Assoc J"},{"key":"525_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103910","volume":"111","author":"A Ivsins","year":"2023","unstructured":"Ivsins A, Warnock A, Small W, Strike C, Kerr T, Bardwell G. A scoping review of qualitative research on barriers and facilitators to the use of supervised consumption services. International Journal of Drug Policy. 2023;111: 103910.","journal-title":"International Journal of Drug Policy"},{"issue":"9","key":"525_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036102","volume":"10","author":"M Piske","year":"2020","unstructured":"Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Greenland S, et al. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. BMJ Open. 2020;10(9): e036102.","journal-title":"BMJ Open"},{"issue":"5","key":"525_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial. JAMA Psychiat. 2016;73(5):447\u201355.","journal-title":"JAMA Psychiat"},{"issue":"38","key":"525_CR10","doi-asserted-by":"publisher","first-page":"E1049","DOI":"10.1503\/cmaj.190344","volume":"191","author":"N Fairbairn","year":"2019","unstructured":"Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. Can Med Assoc J. 2019;191(38):E1049.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"525_CR11","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.9778\/cmajo.20200021","volume":"9","author":"E Eydt","year":"2021","unstructured":"Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, et al. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. CMAJ Open. 2021;9(1):E115.","journal-title":"CMAJ Open"},{"issue":"1","key":"525_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2018","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2018;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"7410","key":"525_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","volume":"327","author":"W van den Brink","year":"2003","unstructured":"van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310.","journal-title":"BMJ"},{"issue":"9291","key":"525_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(01)06529-1","volume":"358","author":"J Rehm","year":"2001","unstructured":"Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet (London, England). 2001;358(9291):1417\u201323.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"525_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jsat.2006.04.007","volume":"31","author":"JC March","year":"2006","unstructured":"March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31(2):203\u201311.","journal-title":"J Subst Abuse Treat"},{"key":"525_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191:55\u201362.","journal-title":"Br J Psychiatry"},{"key":"525_CR17","doi-asserted-by":"crossref","unstructured":"Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. BMC health services research. 2011;11:174-.","DOI":"10.1186\/1472-6963-11-174"},{"issue":"8","key":"525_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386.","journal-title":"N Engl J Med"},{"issue":"3","key":"525_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/ADM.0000000000000887","volume":"16","author":"J Weng","year":"2022","unstructured":"Weng J, Fairbairn N, Sutherland C, Johnson C, Nolan S. Supervised Tablet Injectable Opioid Agonist Therapy (TiOAT): A Strategy to Address Safer Supply for Individuals With an Opioid Use Disorder? J Addict Med. 2022;16(3):258\u201360.","journal-title":"J Addict Med"},{"key":"525_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742","volume":"106","author":"S Glegg","year":"2022","unstructured":"Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. \u201cCOVID just kind of opened a can of whoop-ass\u201d: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. International Journal of Drug Policy. 2022;106: 103742.","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"525_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12954-022-00657-x","volume":"19","author":"K McCrae","year":"2022","unstructured":"McCrae K, Glegg S, Goyer M-\u00c9, Le Foll B, Brar R, Sutherland C, et al. The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19. Harm Reduct J. 2022;19(1):77.","journal-title":"Harm Reduct J"},{"key":"525_CR22","unstructured":"BC Centre on Substance Use. Provincial TiOAT Evaluation: Baseline interview interim results 2022. Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/11\/Interim-Results-from-TiOAT-Study-October-2022.pdf. Accessed 1 Dec 2022."},{"key":"525_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103400","volume":"98","author":"MT Harris","year":"2021","unstructured":"Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, et al. Outcomes of Ottawa, Canada\u2019s Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int J Drug Policy. 2021;98: 103400.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"525_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2105\/AJPH.2020.305612","volume":"110","author":"M Olding","year":"2020","unstructured":"Olding M, Ivsins A, Mayer S, Betsos A, Boyd J, Sutherland C, et al. A Low-Barrier and Comprehensive Community-Based Harm-Reduction Site in Vancouver. Canada American Journal of Public Health. 2020;110(6):833\u20135.","journal-title":"Canada American Journal of Public Health"},{"key":"525_CR25","doi-asserted-by":"crossref","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug and alcohol dependence. 2020:108202.","DOI":"10.1016\/j.drugalcdep.2020.108202"},{"issue":"1","key":"525_CR26","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1186\/s12889-022-14586-8","volume":"22","author":"K Hu","year":"2022","unstructured":"Hu K, Klinkenberg B, Gan WQ, Slaunwhite AK. Spatial-temporal trends in the risk of illicit drug toxicity death in British Columbia. BMC Public Health. 2022;22(1):2121.","journal-title":"BMC Public Health"},{"issue":"4","key":"525_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.17269\/s41997-021-00504-9","volume":"112","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Lappalainen L. The need to prioritize research, policy, and practice to address the overdose epidemic in smaller settings in Canada. Can J Public Health. 2021;112(4):733\u20136.","journal-title":"Can J Public Health"},{"key":"525_CR28","doi-asserted-by":"publisher","first-page":"160940692093788","DOI":"10.1177\/1609406920937880","volume":"19","author":"A Sonday","year":"2020","unstructured":"Sonday A, Ramugondo E, Kathard H. Case Study and Narrative Inquiry as Merged Methodologies: A Critical Narrative Perspective. Int J Qual Methods. 2020;19:1609406920937880.","journal-title":"Int J Qual Methods"},{"issue":"1","key":"525_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1471-2288-11-100","volume":"11","author":"S Crowe","year":"2011","unstructured":"Crowe S, Cresswell K, Robertson A, Huby G, Avery A, Sheikh A. The case study approach. BMC Med Res Methodol. 2011;11(1):100.","journal-title":"BMC Med Res Methodol"},{"key":"525_CR30","doi-asserted-by":"publisher","first-page":"160940692210815","DOI":"10.1177\/16094069221081594","volume":"21","author":"LA Pino Gavidia","year":"2022","unstructured":"Pino Gavidia LA, Adu J. Critical Narrative Inquiry: An Examination of a Methodological Approach. Int J Qual Methods. 2022;21:16094069221081594.","journal-title":"Int J Qual Methods"},{"key":"525_CR31","unstructured":"British Columbia Ministry of Health. B.C. Health System Strategy: Geographic Service Areas. Government of British Columbia; 2016."},{"key":"525_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.drugpo.2016.09.004","volume":"39","author":"AB Collins","year":"2017","unstructured":"Collins AB, Strike C, Guta A, Baltzer Turje R, McDougall P, Parashar S, et al. \u201cWe\u2019re giving you something so we get something in return\u201d: Perspectives on research participation and compensation among people living with HIV who use drugs. Int J Drug Policy. 2017;39:92\u20138.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"525_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"525_CR34","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. What can \u201cthematic analysis\u201d offer health and wellbeing researchers? International journal of qualitative studies on health and well-being. 2014;9.","DOI":"10.3402\/qhw.v9.26152"},{"issue":"1","key":"525_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12874-019-0895-5","volume":"20","author":"L Nyirenda","year":"2020","unstructured":"Nyirenda L, Kumar MB, Theobald S, Sarker M, Simwinga M, Kumwenda M, et al. Using research networks to generate trustworthy qualitative public health research findings from multiple contexts. BMC Med Res Methodol. 2020;20(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"525_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14780887.2015.1021941","volume":"12","author":"M Kornbluh","year":"2015","unstructured":"Kornbluh M. Combatting Challenges to Establishing Trustworthiness in Qualitative Research. Qual Res Psychol. 2015;12(4):397\u2013414.","journal-title":"Qual Res Psychol"},{"issue":"4","key":"525_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11133-021-09500-4","volume":"44","author":"JA Reich","year":"2021","unstructured":"Reich JA. Power, Positionality, and the Ethic of Care in Qualitative Research. Qual Sociol. 2021;44(4):575\u201381.","journal-title":"Qual Sociol"},{"key":"525_CR38","doi-asserted-by":"crossref","unstructured":"Olmos-Vega FM, Stalmeijer RE, Varpio L, Kahlke R. A practical guide to reflexivity in qualitative research: AMEE Guide No. 149. Medical Teacher. 2023;45(3):241\u201351.","DOI":"10.1080\/0142159X.2022.2057287"},{"issue":"1","key":"525_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/0891241620968271","volume":"50","author":"P Bieler","year":"2021","unstructured":"Bieler P, Bister MD, Hauer J, Klausner M, Niew\u00f6hner J, Schmid C, et al. Distributing reflexivity through co-laborative ethnography. J Contemp Ethnogr. 2021;50(1):77\u201398.","journal-title":"J Contemp Ethnogr"},{"issue":"1","key":"525_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13011-022-00463-5","volume":"17","author":"EM Pijl","year":"2022","unstructured":"Pijl EM, Alraja A, Duff E, Cooke C, Dash S, Nayak N, et al. Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review. Substance abuse treatment, prevention, and policy. 2022;17(1):62.","journal-title":"Substance abuse treatment, prevention, and policy"},{"key":"525_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12913-014-0563-8","volume":"14","author":"JP Prunuske","year":"2014","unstructured":"Prunuske JP, St Hill CA, Hager KD, Lemieux AM, Swanoski MT, Anderson GW, et al. Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. BMC Health Serv Res. 2014;14:563.","journal-title":"BMC Health Serv Res"},{"issue":"13","key":"525_CR42","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.12562","volume":"322","author":"PJ Joudrey","year":"2019","unstructured":"Joudrey PJ, Edelman EJ, Wang EA. Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States. JAMA. 2019;322(13):1310\u20132.","journal-title":"JAMA"},{"issue":"1","key":"525_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jrh.12251","volume":"34","author":"JD Brown","year":"2018","unstructured":"Brown JD, Goodin AJ, Talbert JC. Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. J Rural Health. 2018;34(1):6\u201313.","journal-title":"J Rural Health"},{"issue":"7","key":"525_CR44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight. Can J Psychiatry. 2017;62(7):444\u201350.","journal-title":"Can J Psychiatry"},{"key":"525_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108634","volume":"132","author":"PJ Davidson","year":"2022","unstructured":"Davidson PJ, Bowles JM, Faul M, Gaines TL. Spatial proximity and access to buprenorphine or methadone treatment for opioid use disorder in a sample of people misusing opioids in Southern California. J Subst Abuse Treat. 2022;132: 108634.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"525_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):88.","journal-title":"Harm Reduct J"},{"key":"525_CR47","doi-asserted-by":"crossref","unstructured":"Peles E, Schreiber S, Sason A, Adelson M. Earning \u201cTake-Home\u201d Privileges and Long-Term Outcome in a Methadone Maintenance Treatment Program. Journal of addiction medicine. 2011;5(2).","DOI":"10.1097\/ADM.0b013e3181e6ad48"},{"issue":"3","key":"525_CR48","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jsat.2011.12.008","volume":"43","author":"L Richardson","year":"2012","unstructured":"Richardson L, Wood E, Montaner J, Kerr T. Addiction treatment-related employment barriers: the impact of methadone maintenance. J Subst Abuse Treat. 2012;43(3):276\u201384.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"525_CR49","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1331\/JAPhA.2014.13101","volume":"54","author":"American Pharmacists Association","year":"2014","unstructured":"American Pharmacists Association. Pharmacists\u2019 role in addressing opioid abuse, addiction, and diversion. Journal of the American Pharmacists Association\u202f: JAPhA. 2014;54(1):e5-15.","journal-title":"Journal of the American Pharmacists Association : JAPhA"},{"key":"525_CR50","unstructured":"College of Physicians and Surgeons of British Columbia. Professional Standards and Gudelines: Safe Prescribing of Drugs with Potential for Misuse\/Diversion. 2016."},{"key":"525_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103591","volume":"102","author":"C Welsh","year":"2022","unstructured":"Welsh C, Doyon S, Hart K. Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations. Int J Drug Policy. 2022;102: 103591.","journal-title":"Int J Drug Policy"},{"key":"525_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108801","volume":"141","author":"KA Hoffman","year":"2022","unstructured":"Hoffman KA, Foot C, Levander XA, Cook R, Terashima JP, McIlveen JW, et al. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. J Subst Abuse Treat. 2022;141: 108801.","journal-title":"J Subst Abuse Treat"},{"issue":"34","key":"525_CR53","doi-asserted-by":"publisher","first-page":"E967","DOI":"10.1503\/cmaj.200191","volume":"192","author":"A Crabtree","year":"2020","unstructured":"Crabtree A, Lostchuck E, Chong M, Shapiro A, Slaunwhite A. Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada. Can Med Assoc J. 2020;192(34):E967.","journal-title":"Can Med Assoc J"},{"key":"525_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108418","volume":"130","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Ivsins A, Soc\u00edas ME, Kerr T. Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver. Canada Journal of Substance Abuse Treatment. 2021;130: 108418.","journal-title":"Canada Journal of Substance Abuse Treatment"},{"issue":"279","key":"525_CR55","volume":"2021","author":"G Bardwell","year":"1982","unstructured":"Bardwell G, Small W, Lavalley J, McNeil R, Kerr T. \u201cPeople need them or else they\u2019re going to take fentanyl and die\u201d: A qualitative study examining the \u2018problem\u2019 of prescription opioid diversion during an overdose epidemic. Soc Sci Med. 1982;2021(279): 113986.","journal-title":"Soc Sci Med"},{"issue":"6","key":"525_CR56","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.drugpo.2012.10.003","volume":"24","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of \u201cgenerous constraints.\u201d Int J Drug Policy. 2013;24(6):e43-50.","journal-title":"Int J Drug Policy"},{"key":"525_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109109","volume":"228","author":"ME Socias","year":"2021","unstructured":"Socias ME, Grant C, Hayashi K, Bardwell G, Kennedy MC, Milloy MJ, et al. The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver. Canada Drug and alcohol dependence. 2021;228: 109109.","journal-title":"Canada Drug and alcohol dependence"},{"key":"525_CR58","doi-asserted-by":"crossref","unstructured":"Aronowitz S, Meisel ZF. Addressing Stigma to Provide Quality Care to People Who Use Drugs. JAMA Network Open. 2022;5(2):e2146980-e.","DOI":"10.1001\/jamanetworkopen.2021.46980"},{"issue":"1","key":"525_CR59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"key":"525_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108878","volume":"226","author":"HL Surratt","year":"2021","unstructured":"Surratt HL, Otachi JK, McLouth CJ, Vundi N. Healthcare stigma and HIV risk among rural people who inject drugs. Drug Alcohol Depend. 2021;226: 108878.","journal-title":"Drug Alcohol Depend"},{"key":"525_CR61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.socscimed.2017.01.053","volume":"178","author":"A Goodman","year":"2017","unstructured":"Goodman A, Fleming K, Markwick N, Morrison T, Lagimodiere L, Kerr T. \u201cThey treated me like crap and I know it was because I was Native\u201d: The healthcare experiences of Aboriginal peoples living in Vancouver\u2019s inner city. Soc Sci Med. 2017;178:87\u201394.","journal-title":"Soc Sci Med"},{"issue":"1","key":"525_CR62","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12954-022-00725-2","volume":"19","author":"G Bardwell","year":"2022","unstructured":"Bardwell G, Mansoor M, Van Zwietering A, Cleveland E, Snell D, Kerr T. The, \u201cgoldfish bowl\u201d: a qualitative study of the effects of heightened surveillance on people who use drugs in a rural and coastal Canadian setting. Harm Reduct J. 2022;19(1):136.","journal-title":"Harm Reduct J"},{"issue":"1","key":"525_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-021-00479-3","volume":"18","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Austin T, Maher L, Boyd J. Hoots and harm reduction: a qualitative study identifying gaps in overdose prevention among women who smoke drugs. Harm Reduct J. 2021;18(1):29.","journal-title":"Harm Reduct J"},{"issue":"1","key":"525_CR64","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12954-020-00458-0","volume":"18","author":"A Oudshoorn","year":"2021","unstructured":"Oudshoorn A, Sangster Bouck M, McCann M, Zendo S, Berman H, Banninga J, et al. A critical narrative inquiry to understand the impacts of an overdose prevention site on the lives of site users. Harm Reduct J. 2021;18(1):6.","journal-title":"Harm Reduct J"},{"issue":"3","key":"525_CR65","doi-asserted-by":"publisher","first-page":"309","DOI":"10.15288\/jsad.2022.83.309","volume":"83","author":"G Bardwell","year":"2022","unstructured":"Bardwell G. More Than a Pipe Dream? The Need to Adapt Safer Opioid Supply Programs for People Who Smoke Drugs. J Stud Alcohol Drugs. 2022;83(3):309\u201311.","journal-title":"J Stud Alcohol Drugs"},{"issue":"106","key":"525_CR66","first-page":"151","volume":"2014","author":"R McNeil","year":"1982","unstructured":"McNeil R, Small W. \u2018Safer Environment Interventions\u2019: A qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 1982;2014(106):151\u20138.","journal-title":"Soc Sci Med"},{"issue":"7","key":"525_CR67","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1111\/add.15383","volume":"116","author":"V Braithwaite","year":"2021","unstructured":"Braithwaite V, Ti L, Fairbairn N, Ahamad K, McLean M, Harrison S, et al. Building a hospital-based addiction medicine consultation service in Vancouver, Canada: the path taken and lessons learned. Addiction (Abingdon, England). 2021;116(7):1892\u2013900.","journal-title":"Addiction (Abingdon, England)"},{"key":"525_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2018.09.003","volume":"193","author":"N Bozinoff","year":"2018","unstructured":"Bozinoff N, DeBeck K, Milloy MJ, Nosova E, Fairbairn N, Wood E, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver. Canada Drug and alcohol dependence. 2018;193:42\u20137.","journal-title":"Canada Drug and alcohol dependence"},{"issue":"5","key":"525_CR69","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/add.15737","volume":"117","author":"M Kurz","year":"2022","unstructured":"Kurz M, Dale LM, Min JE, Hongdilokkul N, Greiner L, Olley M, et al. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada. Addiction (Abingdon, England). 2022;117(5):1353\u201362.","journal-title":"Addiction (Abingdon, England)"},{"issue":"9","key":"525_CR70","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/infdis\/jir032","volume":"203","author":"MJ Milloy","year":"2011","unstructured":"Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response Effect of Incarceration Events on Nonadherence to HIV Antiretroviral Therapy Among Injection Drug Users. J Infect Dis. 2011;203(9):1215\u201321.","journal-title":"J Infect Dis"},{"issue":"6","key":"525_CR71","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1080\/09540120802511869","volume":"21","author":"W Small","year":"2009","unstructured":"Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21(6):708\u201314.","journal-title":"AIDS Care"},{"issue":"1","key":"525_CR72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13011-022-00504-z","volume":"17","author":"H Palis","year":"2022","unstructured":"Palis H, Zhao B, Young P, Korchinski M, Greiner L, Nicholls T, et al. Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study. Substance abuse treatment, prevention, and policy. 2022;17(1):77.","journal-title":"Substance abuse treatment, prevention, and policy"},{"issue":"3","key":"525_CR73","doi-asserted-by":"publisher","first-page":"E907","DOI":"10.9778\/cmajo.20200243","volume":"9","author":"SA Kinner","year":"2021","unstructured":"Kinner SA, Gan W, Slaunwhite A. Fatal overdoses after release from prison in British Columbia: a retrospective data linkage study. CMAJ Open. 2021;9(3):E907.","journal-title":"CMAJ Open"},{"issue":"1","key":"525_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1940-0640-7-3","volume":"7","author":"IA Binswanger","year":"2012","unstructured":"Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7(1):3.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"525_CR75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40352-020-00113-7","volume":"8","author":"EN Waddell","year":"2020","unstructured":"Waddell EN, Baker R, Hartung DM, Hildebran CJ, Nguyen T, Collins DM, et al. Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. Health Justice. 2020;8(1):18.","journal-title":"Health Justice"},{"issue":"8","key":"525_CR76","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/add.13803","volume":"112","author":"A Bukten","year":"2017","unstructured":"Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction (Abingdon, England). 2017;112(8):1432\u20139.","journal-title":"Addiction (Abingdon, England)"},{"key":"525_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drugalcdep.2015.06.011","volume":"153","author":"RJ Winter","year":"2015","unstructured":"Winter RJ, Stoov\u00e9 M, Degenhardt L, Hellard ME, Spelman T, Jenkinson R, et al. Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland. Australia Drug and alcohol dependence. 2015;153:43\u20139.","journal-title":"Australia Drug and alcohol dependence"},{"issue":"1","key":"525_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13722-019-0145-5","volume":"14","author":"PJ Joudrey","year":"2019","unstructured":"Joudrey PJ, Khan MR, Wang EA, Scheidell JD, Edelman EJ, McInnes DK, et al. A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract. 2019;14(1):17.","journal-title":"Addict Sci Clin Pract"},{"key":"525_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m772","volume":"368","author":"LA Pearce","year":"2020","unstructured":"Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368: m772.","journal-title":"BMJ"},{"issue":"1","key":"525_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.amepre.2020.07.006","volume":"60","author":"ME Soc\u00edas","year":"2021","unstructured":"Soc\u00edas ME, Dong H, Wood E, Nolan S, Hayashi K, Kerr T, et al. Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting. Am J Prev Med. 2021;60(1):57\u201363.","journal-title":"Am J Prev Med"},{"issue":"1","key":"525_CR81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13012-019-0861-y","volume":"14","author":"EN Woodward","year":"2019","unstructured":"Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci. 2019;14(1):26.","journal-title":"Implement Sci"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-023-00525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-023-00525-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-023-00525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T19:03:15Z","timestamp":1677870195000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-023-00525-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1186\/s13011-023-00525-2","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of British Columbia\/Providence Health Care Research Ethics Board and Island Health Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}